Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH

Protein Science

Volumn 8, Issue 8, 1999, Pages 1702-1707

  Xie, Dong ^a   Gulnik, Sergei ^a   Gustchina, Elena ^a   Yu, Betty ^a   Shao, Wei ^a   Qoronfleh, Walid ^a   Nathan, Anand ^a   Erickson, John W ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Dimer stability; Drug resistant; HIV 1 protease; Sedimentation equilibrium

Indexed keywords

PROTEINASE;

ARTICLE; BINDING AFFINITY; DISSOCIATION CONSTANT; ENZYME STABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; MUTAGENESIS; NONHUMAN; PH; PRIORITY JOURNAL; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032771020     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.8.8.1702     Document Type: Article

References (29)

1. Darke PL. 1994. Stability of dimeric retroviral proteases. Methods Enzymol 241:104-127.
2. Darke PL, Jordan SP, Hall DL, Zugay JA, Shafer JA, Kuo LC. 1994. Dissociation and association of the HIV-1 protease dimer subunits: Equilibria and rates. Biochemistry 33:98-105.
3. Darke PL, Leu C-T, Davis L, Heimbach J, Diehl R, Hill W, Dixon R, Sigal I. 1989. Human immunodeficiency virus protease: Bacterial expression and characterization of the purified aspartic protease. J Biol Chem 264:2307-2312.
4. Davies DR. 1990. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem 19:189-215.
5. Dunn BM, Gustchina A, Wlodawer A, Kay J. 1994. Subsite preferences of retroviral proteinases. Methods Enzymol 241:254-278.
6. Furfine ES, D'Souza E, Ingold KJ, Leban JJ, Spector T, Porter DJ. 1992. Two-step binding mechanism for HIV protease inhibitors. Biochemistry 31:7886-7891.
7. Grant S, Deckman I, Culp J, Minnich M, Brooks I, Hensley P, Debouck C, Meek T. 1992. Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV protease. Biochemistry 31:9491-9501.
8. Gulnik S, Suvorov L, Liu B, Yu B, Anderson B, Mitsuya H, Erickson J. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
9. Hensley P, Moffat K, Edelstein SJ. 1975. Influence of inositol hexaphosphate binding on subunit dissociation in methemoglobin. J Biol Chem 250:9391-9396.
10. Johnson ML, Frasier SG. 1985. Nonlinear least-squares analysis. Methods Enzymol 117:301-342.
11. Johnson WC Jr. 1990. Protein secondary structure and circular dichroism: A practical guide. Proteins Struct Fund Genet 7:205-214.
12. Kaplan AH, Swanstrom R. 1991. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci USA 88:4528-4532.
13. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon R, Scolnick EM, Sigal IS. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690.
14. Kotler M, Arad G, Hughes S. 1992. Human immunodeficiency virus type 1 Gag-protease fusion proteins are enzymatically active. J Virol 66:6781-6783.
15. Kotler M, Simm M, Zhao Y, Sova P, Chao W, Ohnona S-F, Roller R, Krachmarov C, Potash M, Volsky D. 1997. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol 71:5774-5781.
16. Kunkel TA, Bebenek K, McClary J. 1991. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol 204:125-139.
17. Kuzmic P. 1993. Kinetic assay for HIV proteinase subunit dissociation. Biochem Biophys Res Commun 191:998-1003.
18. Meek TD, Lambert DM, Dreyer GB, Carr TJ, Tomaszek TA Jr, Moore ML, Strickler JE, Debouck C, Hyland LJ, Matthews TJ, Metcalf BW, Petteway SR. 1990. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343:90-92.
19. Mildner AM, Rothrock DJ, Leone JW, Bannow CA, Lull JM, Reardon IM, Sarcich JL, Howe WJ, Tomich C-SC, Smith CW, Heinrikson RL, Tomasselli AG. 1994. The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33:9405-9413.
20. Shao W, Everitt L, Manchester M, Loeb DD, Hutchison CA, Swanstrom R. 1997. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc Natl Acad Sci USA 94:2243-2248.
21. Skulnick HI, Johnson PD, Aristoff PA, Morris JK, Lovasz KD, Howe WJ, Watenpaugh KD, Janakiraman MN, Anderson DJ, Reischer RJ, et al. 1997. Structure-based design of nonpeptidic HIV protease inhibitors: The sulfonamide-substituted cyclooctylpyramones. J Med Chem 40:1149-1164.
22. Stryer L. 1965. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites. J Mol Biol 13:482-495.
23. Swanstrom R, Wills JW. 1997. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. New York: Cold Spring Harbor Laboratory Press. pp 263-334.
24. Todd MJ, Semo N, Freire E. 1998. The structural stability of the HIV-1 protease. J Mol Biol 253:475-488.
25. Vogt VM. 1996. Proteolytic processing and particle maturation. Curr Top Microbiol Immunol 214:95-131.
26. Wlodawer A, Erickson JW. 1993. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 62:543-585.
27. Wondrak EM, Louis JM. 1996. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35:12957-12962.
28. Wyman J, Gill S. 1990. Binding and linkage: Functional chemistry of biological macromolecules. Mill Valley, California: University Science Books.
29. Zamyatnin AA. 1972. Protein volume in solution. Prog Biophys Mol Biol 24:107-123.